The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians

Stein, 2001, Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients, J Clin Oncol, 19, 666, 10.1200/JCO.2001.19.3.666 Stein, 2006, Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure, World J Urol, 24, 296, 10.1007/s00345-006-0061-7 Dalbagni, 2001, Cystectomy for bladder cancer: a contemporary series, J Urol, 165, 1111 Alfred Witjes, 2016, Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer, Eur Urol 2003, Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis, Lancet, 361, 1927, 10.1016/S0140-6736(03)13580-5 Winquist, 2004, Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis, J Urol, 171, 561 2005, Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration, Eur Urol, 48, 202, 10.1016/j.eururo.2005.04.006 Booth, 2014, Perioperative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study, Cancer, 120, 1630, 10.1002/cncr.28510 Burger, 2012, Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire, Eur Urol, 61, 1070, 10.1016/j.eururo.2012.01.039 Reardon, 2015, Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides, Eur Urol, 67, 165, 10.1016/j.eururo.2014.01.009 2009 Witjes, 2014, EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines, Eur Urol, 65, 778, 10.1016/j.eururo.2013.11.046 Feifer, 2011, Multi-institutional quality-of-care initiative for non-metastatic, muscle-invasive, transitional cell carcinoma of the bladder, J Clin Oncol, 29, 240, 10.1200/jco.2011.29.7_suppl.240 Raghavan, 2012, Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer, Semin Oncol, 39, 588, 10.1053/j.seminoncol.2012.08.003 Meeks, 2012, A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer, Eur Urol, 62, 523, 10.1016/j.eururo.2012.05.048 Fedeli, 2011, Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007, J Urol, 185, 72 Krabbe, 2015, Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer, Can J Urol, 22, 7865 Gandaglia, 2014, The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study, Eur Urol, 66, 561, 10.1016/j.eururo.2014.01.014 Johnson, 2014, Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity, BJU Int, 114, 221, 10.1111/bju.12585 Canter, 2011, Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy, Urology, 77, 160, 10.1016/j.urology.2010.03.091 Feifer, 2011, Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy, Eur Urol, 59, 978, 10.1016/j.eururo.2011.01.014 Galsky, 2011, A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy, Lancet Oncol, 12, 211, 10.1016/S1470-2045(10)70275-8 Thompson, 2014, Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients, BJU Int, 113, E17, 10.1111/bju.12274 Raj, 2006, Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer, J Clin Oncol, 24, 3095, 10.1200/JCO.2005.04.3091 Grossman, 2003, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, 349, 859, 10.1056/NEJMoa022148 Zargar, 2015, Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer, Eur Urol, 67, 241, 10.1016/j.eururo.2014.09.007 Galsky, 2015, Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer, Cancer, 121, 2586, 10.1002/cncr.29387 van de Putte, 2016, Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin, World J Urol, 34, 157, 10.1007/s00345-015-1636-y Scosyrev, 2011, Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710), BJU Int, 108, 693, 10.1111/j.1464-410X.2011.10582.x